US 11,779,633 B2
Glucagon-like peptide 1 receptor agonists and uses thereof
Yang Wei, Yorktown Heights, NY (US); Haruka Okamoto, New York, NY (US); Jesper Gromada, Scarsdale, NY (US); Samuel Davis, New York, NY (US); and Andrew J. Murphy, Croton-on-Hudson, NY (US)
Assigned to Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
Filed by Regeneran Pharmaceuticals, Inc., Tarrytown, NY (US)
Filed on May 27, 2021, as Appl. No. 17/332,215.
Application 17/332,215 is a division of application No. 16/137,662, filed on Sep. 21, 2018, granted, now 11,045,522.
Claims priority of provisional application 62/562,283, filed on Sep. 22, 2017.
Prior Publication US 2021/0283225 A1, Sep. 16, 2021
Int. Cl. A61K 38/26 (2006.01); C07K 16/28 (2006.01); C07K 14/605 (2006.01); A61P 3/04 (2006.01); A61P 3/10 (2006.01); A61K 31/155 (2006.01); A61K 31/5415 (2006.01); C07K 16/08 (2006.01); C12N 15/62 (2006.01); A61K 38/00 (2006.01)
CPC A61K 38/26 (2013.01) [A61K 31/155 (2013.01); A61K 31/5415 (2013.01); A61P 3/04 (2018.01); A61P 3/10 (2018.01); C07K 14/605 (2013.01); C07K 16/082 (2013.01); C07K 16/2869 (2013.01); C12N 15/62 (2013.01); A61K 38/00 (2013.01); C07K 2319/00 (2013.01)] 5 Claims
 
1. A method of lowering blood sugar level in a subject in need thereof, wherein the method comprises administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of a fusion protein consisting of a glucagon-like peptide 1 (GLP1) variant and a stabilizing domain, and wherein: (i) the GLP1 variant consists of SEQ ID NO: 6; (ii) the stabilizing domain is an antibody or antigen-binding fragment thereof that binds specifically to GLP1 receptor; and (iii) the fusion protein has enhanced resistance to proteolytic cleavage and/or enhanced blood glucose lowering ability.